1. New Zealand community mental healthcare provider experience in schizophrenia management with 3-monthly paliperidone palmitate
- Author
-
Wayne Miles and Cathal Cassidy
- Subjects
Paliperidone Palmitate ,relapse ,medicine.medical_specialty ,business.industry ,long-acting antipsychotic agents ,Schizophrenia (object-oriented programming) ,Perspective (graphical) ,Patient management ,Mental healthcare ,Clinical Practice ,schizophrenia ,Psychiatry and Mental health ,Caregivers ,Medicine ,Humans ,survey ,business ,Psychiatry ,Antipsychotic Agents ,New Zealand - Abstract
Objectives: To understand the impact of 3-monthly treatment with paliperidone palmitate on patient management, including non-adherence and relapse, from a psychiatrist and nurse perspective for 73 patients enrolled in a patient familiarisation programme (PFP) in New Zealand. Methods: An online questionnaire was sent to clinicians with at least 6 months of regular interaction with PFP patients. Questions addressed treatment effectiveness and patient management changes. Analyses are descriptive only and do not represent patient or carer perspectives. Results: Seven psychiatrists, representing 58 of 73 (79.5%) of patients, and 17 nurses responded to the survey. Psychiatrists were satisfied with efficacy and tolerability and relapse prevention. Treatment goals were either ‘met’ (2/7; 28.6%) or ‘exceeded’ (5/7; 71.4%). The focus on adherence issues decreased and the focus on life areas and recovery goals increased. Conclusions: From the clinician perspective, 3-monthly paliperidone palmitate offers patients the potential to remain adherent and improve social functioning.
- Published
- 2020